Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

NCT00203372 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Bevacizumab 7.5 and TAC
DRUG: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
DRUG: Bevacizumab 15 and TAC
DRUG: Placebo 15 and TAC

Sponsor

Translational Oncology Research International

Collaborators

[object Object]